Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 171


Impact of persistent, frequent regurgitation on quality of life in heartburn responders treated with acid suppression: a multinational primary care study.

Kahrilas PJ, Howden CW, Wernersson B, Denison H, Nuevo J, Gisbert JP.

Aliment Pharmacol Ther. 2013 May;37(10):1005-10. doi: 10.1111/apt.12298. Epub 2013 Apr 5.


Prevalence of and impact of pantoprazole on nocturnal heartburn and associated sleep complaints in patients with erosive esophagitis.

Kindt S, Imschoot J, Tack J.

Dis Esophagus. 2011 Nov;24(8):531-7. doi: 10.1111/j.1442-2050.2011.01189.x. Epub 2011 Mar 18.


Frequency and clinical implications of supraesophageal and dyspeptic symptoms in gastroesophageal reflux disease.

Mearin F, Ponce J, Ponce M, Balboa A, Gónzalez MA, Zapardiel J.

Eur J Gastroenterol Hepatol. 2012 Jun;24(6):665-74. doi: 10.1097/MEG.0b013e3283512139.


Impact of regurgitation on health-related quality of life in gastro-oesophageal reflux disease before and after short-term potent acid suppression therapy.

Kahrilas PJ, Jonsson A, Denison H, Wernersson B, Hughes N, Howden CW.

Gut. 2014 May;63(5):720-6. doi: 10.1136/gutjnl-2013-304883. Epub 2013 Jul 5.


Regurgitation is less responsive to acid suppression than heartburn in patients with gastroesophageal reflux disease.

Kahrilas PJ, Jonsson A, Denison H, Wernersson B, Hughes N, Howden CW.

Clin Gastroenterol Hepatol. 2012 Jun;10(6):612-9. doi: 10.1016/j.cgh.2012.01.022. Epub 2012 Feb 14.


The burden of illness of gastro-oesophageal reflux disease: impact on work productivity.

Dean BB, Crawley JA, Schmitt CM, Wong J, Ofman JJ.

Aliment Pharmacol Ther. 2003 May 15;17(10):1309-17.


Clinical trial: esomeprazole for moderate-to-severe nighttime heartburn and gastro-oesophageal reflux disease-related sleep disturbances.

Johnson D, Crawley JA, Hwang C, Brown K.

Aliment Pharmacol Ther. 2010 Jul;32(2):182-90. doi: 10.1111/j.1365-2036.2010.04339.x. Epub 2010 Apr 29.


Use of the Montreal global definition as an assessment of quality of life in reflux disease.

Sawaya RA, Macgill A, Parkman HP, Friedenberg FK.

Dis Esophagus. 2012 Aug;25(6):477-83. doi: 10.1111/j.1442-2050.2011.01271.x. Epub 2011 Oct 3.


The effect of dexlansoprazole MR on nocturnal heartburn and GERD-related sleep disturbances in patients with symptomatic GERD.

Fass R, Johnson DA, Orr WC, Han C, Mody R, Stern KN, Pilmer BL, Perez MC.

Am J Gastroenterol. 2011 Mar;106(3):421-31. doi: 10.1038/ajg.2010.458. Epub 2011 Jan 11.


Health-related quality of life improves with treatment-related GERD symptom resolution after adjusting for baseline severity.

Revicki DA, Zodet MW, Joshua-Gotlib S, Levine D, Crawley JA.

Health Qual Life Outcomes. 2003 Nov 29;1:73.


Consequences of frequent nocturnal gastro-oesophageal reflux disease among employed adults: symptom severity, quality of life and work productivity.

Dubois RW, Aguilar D, Fass R, Orr WC, Elfant AB, Dean BB, Harper AS, Yu HT, Melmed GY, Lynn R, Singh A, Tedeschi M.

Aliment Pharmacol Ther. 2007 Feb 15;25(4):487-500.


Distinguishing the impact of dexlansoprazole on heartburn vs. regurgitation in patients with gastro-oesophageal reflux disease.

Peura DA, Pilmer B, Hunt B, Mody R, Perez MC.

Aliment Pharmacol Ther. 2013 Nov;38(10):1303-11. doi: 10.1111/apt.12504. Epub 2013 Sep 30.


Effect of proton-pump inhibitor treatment on symptoms and quality of life in GERD patients depends on the symptom-reflux association.

Aanen MC, Weusten BL, Numans ME, de Wit NJ, Samsom M, Smout AJ.

J Clin Gastroenterol. 2008 May-Jun;42(5):441-7. doi: 10.1097/MCG.0b013e318074dd62.


Impact of gastroesophageal reflux disease on patients' daily lives: a European observational study in the primary care setting.

Gisbert JP, Cooper A, Karagiannis D, Hatlebakk J, Agréus L, Jablonowski H, Zapardiel J.

Health Qual Life Outcomes. 2009 Jul 2;7:60. doi: 10.1186/1477-7525-7-60.


Airway symptoms and sleeping difficulties in operated and non-operated patients with gastroesophageal reflux disease.

Johannessen R, Petersen H, Olberg P, Johnsen G, Fjøsne U, Kleveland PM.

Scand J Gastroenterol. 2012 Jul;47(7):762-9. doi: 10.3109/00365521.2012.683041. Epub 2012 May 10.


Association of body mass index with heartburn, regurgitation and esophagitis: results of the Progression of Gastroesophageal Reflux Disease study.

Nocon M, Labenz J, Jaspersen D, Meyer-Sabellek W, Stolte M, Lind T, Malfertheiner P, Willich SN.

J Gastroenterol Hepatol. 2007 Nov;22(11):1728-31.


Heartburn and regurgitation have different impacts on life quality of patients with gastroesophageal reflux disease.

Lee SW, Lien HC, Lee TY, Yang SS, Yeh HJ, Chang CS.

World J Gastroenterol. 2014 Sep 14;20(34):12277-82. doi: 10.3748/wjg.v20.i34.12277.


Night-time and daytime atypical manifestations of gastro-oesophageal reflux disease: frequency, severity and impact on health-related quality of life.

Dean BB, Aguilar D, Johnson LF, McGuigan JE, Orr WC, Fass R, Yan N, Morgenstern D, Dubois RW.

Aliment Pharmacol Ther. 2008 Feb 15;27(4):327-37. Epub 2007 Nov 13.

Supplemental Content

Support Center